Drug Detail:Ultomiris (Ravulizumab [ rav-ue-liz-ue-mab ])
Generic Name: ravulizumab 300mg in 30mL
Drug Class: Selective immunosuppressants
Important Dosage Information
ULTOMIRIS may be administered as an intravenous infusion (ULTOMIRIS vial for intravenous administration) in adult or pediatric patients one month of age and older or as a subcutaneous injection for maintenance (ULTOMIRIS on-body delivery system for subcutaneous administration) in adult patients.
Vials are intended for intravenous use only, and on-body delivery systems (prefilled cartridge and on-body injector) are intended for subcutaneous maintenance use only.
Recommended Vaccination and Prophylaxis
Vaccinate patients for meningococcal disease according to current ACIP guidelines to reduce the risk of serious infection [see Warnings and Precautions (5.1, 5.3)].
Provide 2 weeks of antibacterial drug prophylaxis to patients if ULTOMIRIS must be initiated immediately and vaccines are administered less than 2 weeks before starting ULTOMIRIS therapy.
Healthcare professionals who prescribe ULTOMIRIS must enroll in the ULTOMIRIS REMS [see Warnings and Precautions (5.1)].
Intravenous Administration in Adult and Pediatric Patients with PNH, aHUS, or gMG
The recommended intravenous ULTOMIRIS loading and maintenance dosing in adult and pediatric patients, one month of age or older weighing 5 kg or greater, with PNH or aHUS, or in adult patients with gMG weighing 40 kg or greater, is based on the patient's body weight, as shown in Table 1, with maintenance doses administered every 4 or 8 weeks, starting 2 weeks after loading dose.
The intravenous (IV) dosing schedule is allowed to occasionally vary within 7 days of the scheduled infusion day (except for the first maintenance dose of ULTOMIRIS); but subsequent doses should be administered according to the original schedule.
Following a missed intravenous ULTOMIRIS dose, the patient should contact their health care provider immediately.
Indications | Body Weight Range (kg) |
Loading Dose (mg)† |
Maintenance Dose (mg) and Dosing Interval | |
---|---|---|---|---|
|
||||
PNH and aHUS | 5 to less than 10 | 600 | 300 | Every 4 weeks |
10 to less than 20 | 600 | 600 | ||
20 to less than 30 | 900 | 2,100 | Every 8 weeks |
|
30 to less than 40 | 1,200 | 2,700 | ||
PNH, aHUS, and gMG | 40 to less than 60 | 2,400 | 3,000 | Every 8 weeks |
60 to less than 100 | 2,700 | 3,300 | ||
100 or greater | 3,000 | 3,600 |
Refer to Table 2 for treatment initiation instructions in patients who are complement inhibitor treatment-naïve, or switching treatment from subcutaneous (SUBQ) administration of ULTOMIRIS or eculizumab.
Population | Weight-based ULTOMIRIS IV Loading Dose | Time of First ULTOMIRIS IV Weight-based Maintenance Dose |
---|---|---|
|
||
Not currently on ULTOMIRIS or eculizumab treatment | At treatment start | 2 weeks after ULTOMIRIS IV loading dose |
Currently treated with eculizumab | At time of next scheduled eculizumab dose | 2 weeks after ULTOMIRIS IV loading dose |
Currently treated with ULTOMIRIS on-body delivery system for subcutaneous administration (SUBQ)* | Not applicable | 1 week after last ULTOMIRIS SUBQ maintenance dose |
Subcutaneous Administration in Adult Patients with PNH or aHUS
Subcutaneous (SUBQ) dosing of ULTOMIRIS is not approved for use in pediatric patients.
The recommended subcutaneous ULTOMIRIS maintenance dose is 490 mg once weekly in adult patients greater than or equal to 40 kg body weight with PNH or aHUS. The 490 mg dose of ULTOMIRIS is delivered using 2 on-body delivery systems. Each on-body delivery system consists of 1 on-body injector and 1 prefilled cartridge containing 245 mg of ravulizumab.
The subcutaneous dosing schedule is allowed to occasionally vary by ± 1 day of the scheduled dose day, but the subsequent dose should be administered according to the original schedule.
Following a missed or partial subcutaneous ULTOMIRIS dose, the patient should contact their health care provider immediately.
Refer to Table 3 for treatment initiation instructions in patients who are complement inhibitor treatment-naïve, or switching treatment from intravenous administration of ULTOMIRIS or eculizumab.
Population | Weight-based ULTOMIRIS IV Loading Dose* | Time of First ULTOMIRIS 490 mg SUBQ Maintenance Dose |
---|---|---|
|
||
Not currently on ULTOMIRIS or eculizumab treatment | At treatment start | 2 weeks after ULTOMIRIS IV loading dose |
Currently treated with eculizumab | At time of next scheduled eculizumab dose | 2 weeks after ULTOMIRIS IV loading dose |
Currently treated with ULTOMIRIS intravenous (IV) administration | Not applicable | 8 weeks after last ULTOMIRIS IV maintenance dose |
Dosing Considerations
Supplemental Dose of ULTOMIRIS
Plasma exchange (PE), plasmapheresis (PP), and intravenous immunoglobulin (IVIg) have been shown to reduce ULTOMIRIS serum levels. A supplemental dose of ULTOMIRIS is required in the setting of PE, PP, or IVIg (Table 4).
Body Weight Range (kg) | Most Recent ULTOMIRIS Dose (mg) | Supplemental Dose (mg) following each PE or PP Intervention | Supplemental Dose (mg) following Completion of an IVIg Cycle |
---|---|---|---|
Abbreviations: IVIg = intravenous immunoglobulin; PE = plasma exchange; PP = plasmapheresis | |||
|
|||
40 to less than 60 | 2,400 | 1,200 | 600 |
3,000 | 1,500 | ||
60 to less than 100 | 2,700 | 1,500 | 600 |
3,300 | 1,800 | ||
100 or greater | 3,000 | 1,500 | 600 |
3,600 | 1,800 | ||
Timing of ULTOMIRIS Supplemental Dose | Within 4 hours following each PE or PP intervention | Within 4 hours following completion of an IVIg cycle |
Preparation and Administration
Preparation of ULTOMIRIS Vials for Intravenous Administration
Each vial of ULTOMIRIS is intended for single-dose only.
ULTOMIRIS vials are for intravenous administration by a healthcare provider and are intended for intravenous administration only.
Dilute before use.
Do not mix ULTOMIRIS 100 mg/mL (3 mL and 11 mL vials) and 10 mg/mL (30 mL vial) concentrations together.
Use aseptic technique to prepare ULTOMIRIS as follows:
- 1.
- The number of vials to be diluted is determined based on the individual patient's weight and the prescribed dose [see Dosage and Administration (2.2)].
- 2.
- Prior to dilution, visually inspect the solution in the vials; the solution should be free of any particulate matter or precipitation. Do not use if there is evidence of particulate matter or precipitation.
- 3.
- Withdraw the calculated volume of ULTOMIRIS from the appropriate number of vials and dilute in an infusion bag using 0.9% Sodium Chloride Injection, USP to a final concentration of:
- 50 mg/mL for the 3 mL and 11 mL vial sizes or
- 5 mg/mL for the 30 mL vial size.
The product should be mixed gently. Do not shake. Protect from light. Do not freeze.
Refer to the following reference tables for IV preparation and minimum infusion duration:
-
- ULTOMIRIS 100 mg/mL (3 mL and 11 mL vials): see Table 5 (loading doses), Table 6 (maintenance doses), and Table 7 (supplemental doses)
- ULTOMIRIS 10 mg/mL (30 mL vial): see Table 8 (loading doses), Table 9 (maintenance doses), and Table 10 (supplemental doses)
- 4.
- Administer the prepared solution immediately following preparation.
- 5.
- If the diluted ULTOMIRIS infusion solution is not used immediately, storage under refrigeration at 2°C - 8°C (36°F - 46°F) must not exceed 24 hours taking into account the expected infusion time. Once removed from refrigeration, administer the diluted ULTOMIRIS infusion solution within 6 hours if prepared with ULTOMIRIS 30 mL vials or within 4 hours if prepared with ULTOMIRIS 3 mL or 11 mL vials.
Intravenous Administration of ULTOMIRIS (Healthcare Providers)
Only administer as an intravenous infusion through a 0.2 or 0.22 micron filter.
Dilute ULTOMIRIS to a final concentration of:
- 50 mg/mL for the 3 mL and 11 mL vial sizes or
- 5 mg/mL for the 30 mL vial size.
Prior to administration, allow the admixture to adjust to room temperature (18°C - 25°C, 64°F - 77°F). Do not heat the admixture in a microwave or with any heat source other than ambient air temperature.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Body Weight Range (kg)* |
Loading Dose (mg) | ULTOMIRIS Volume (mL) | Volume of NaCl Diluent† (mL) | Total Volume (mL) | Minimum Infusion Time (hr) | Maximum Infusion Rate (mL/hr) |
---|---|---|---|---|---|---|
|
||||||
5 to less than 10‡ | 600 | 6 | 6 | 12 | 1.4 | 9 |
10 to less than 20‡ | 600 | 6 | 6 | 12 | 0.8 | 15 |
20 to less than 30‡ | 900 | 9 | 9 | 18 | 0.6 | 30 |
30 to less than 40‡ | 1,200 | 12 | 12 | 24 | 0.5 | 48 |
40 to less than 60 | 2,400 | 24 | 24 | 48 | 0.8 | 60 |
60 to less than 100 | 2,700 | 27 | 27 | 54 | 0.6 | 90 |
100 or greater | 3,000 | 30 | 30 | 60 | 0.4 | 150 |
Body Weight Range (kg)* |
Maintenance Dose (mg) | ULTOMIRIS Volume (mL) | Volume of NaCl Diluent† (mL) | Total Volume (mL) | Minimum Infusion Time (hr) | Maximum Infusion Rate (mL/hr) |
---|---|---|---|---|---|---|
|
||||||
5 to less than 10‡ | 300 | 3 | 3 | 6 | 0.8 | 8 |
10 to less than 20‡ | 600 | 6 | 6 | 12 | 0.8 | 15 |
20 to less than 30‡ | 2,100 | 21 | 21 | 42 | 1.3 | 33 |
30 to less than 40‡ | 2,700 | 27 | 27 | 54 | 1.1 | 50 |
40 to less than 60 | 3,000 | 30 | 30 | 60 | 0.9 | 67 |
60 to less than 100 | 3,300 | 33 | 33 | 66 | 0.7 | 95 |
100 or greater | 3,600 | 36 | 36 | 72 | 0.5 | 144 |
Body Weight Range (kg)* | Supplemental Dose (mg) | ULTOMIRIS Volume (mL) | Volume of NaCl Diluent† (mL) | Total Volume (mL) | Minimum Infusion Time (hr) |
Maximum Infusion Rate (mL/hr) |
---|---|---|---|---|---|---|
Note: Refer to Table 4 for selection of ravulizumab supplemental dose | ||||||
|
||||||
40 to less than 60 | 600 | 6 | 6 | 12 | 0.25 | 48 |
1,200 | 12 | 12 | 24 | 0.42 | 57 | |
1,500 | 15 | 15 | 30 | 0.5 | 60 | |
60 to less than 100 | 600 | 6 | 6 | 12 | 0.20 | 60 |
1,500 | 15 | 15 | 30 | 0.36 | 83 | |
1,800 | 18 | 18 | 36 | 0.42 | 86 | |
100 or greater | 600 | 6 | 6 | 12 | 0.17 | 71 |
1,500 | 15 | 15 | 30 | 0.25 | 120 | |
1,800 | 18 | 18 | 36 | 0.28 | 129 |
Body Weight Range (kg)* |
Loading Dose (mg) | ULTOMIRIS Volume (mL) | Volume of NaCl Diluent† (mL) | Total Volume (mL) | Minimum Infusion Time (hr) | Maximum Infusion Rate (mL/hr) |
---|---|---|---|---|---|---|
|
||||||
5 to less than 10‡ | 600 | 60 | 60 | 120 | 3.8 | 32 |
10 to less than 20‡ | 600 | 60 | 60 | 120 | 1.9 | 64 |
20 to less than 30‡ | 900 | 90 | 90 | 180 | 1.5 | 120 |
30 to less than 40‡ | 1,200 | 120 | 120 | 240 | 1.3 | 185 |
40 to less than 60 | 2,400 | 240 | 240 | 480 | 1.9 | 253 |
60 to less than 100 | 2,700 | 270 | 270 | 540 | 1.7 | 318 |
100 or greater | 3,000 | 300 | 300 | 600 | 1.8 | 334 |
Body Weight Range (kg)* |
Maintenance Dose (mg) | ULTOMIRIS Volume (mL) | Volume of NaCl Diluent† (mL) | Total Volume (mL) | Minimum Infusion Time (hr) | Maximum Infusion Rate (mL/hr) |
---|---|---|---|---|---|---|
|
||||||
5 to less than 10‡ | 300 | 30 | 30 | 60 | 1.9 | 32 |
10 to less than 20‡ | 600 | 60 | 60 | 120 | 1.9 | 64 |
20 to less than 30‡ | 2,100 | 210 | 210 | 420 | 3.3 | 128 |
30 to less than 40‡ | 2,700 | 270 | 270 | 540 | 2.8 | 193 |
40 to less than 60 | 3,000 | 300 | 300 | 600 | 2.3 | 261 |
60 to less than 100 | 3,300 | 330 | 330 | 660 | 2 | 330 |
100 or greater | 3,600 | 360 | 360 | 720 | 2.2 | 328 |
Body Weight Range (kg)* | Supplemental Dose (mg) | ULTOMIRIS Volume (mL) | Volume of NaCl Diluent† (mL) | Total Volume (mL) | Minimum Infusion Time (hr) | Maximum Infusion Rate (mL/hr) |
---|---|---|---|---|---|---|
Note: Refer to Table 4 for selection of ravulizumab supplemental dose | ||||||
|
||||||
40 to less than 60 | 600 | 60 | 60 | 120 | 0.5 | 240 |
1,200 | 120 | 120 | 240 | 1.0 | 240 | |
1,500 | 150 | 150 | 300 | 1.2 | 250 | |
60 to less than 100 | 600 | 60 | 60 | 120 | 0.4 | 300 |
1,500 | 150 | 150 | 300 | 1.0 | 300 | |
1,800 | 180 | 180 | 360 | 1.1 | 327 | |
100 or greater | 600 | 60 | 60 | 120 | 0.4 | 300 |
1,500 | 150 | 150 | 300 | 1.0 | 300 | |
1,800 | 180 | 180 | 360 | 1.1 | 327 |
If an adverse reaction occurs during the intravenous administration of ULTOMIRIS, the infusion may be slowed or stopped at the discretion of the physician. Monitor the patient for at least 1 hour following completion of the infusion for signs or symptoms of an infusion-related reaction.
Preparation of ULTOMIRIS On-Body Delivery System for Subcutaneous Administration
ULTOMIRIS on-body delivery system is intended for administration by patients/caregivers. Patients/caregivers may administer after training from a healthcare provider. Refer to the Instructions for Use for detailed instructions on how to use and administer subcutaneous ULTOMIRIS.
- Remove 2 cartons of ULTOMIRIS on-body delivery system for subcutaneous administration from the refrigerator. Two on-body injectors and 2 prefilled cartridges are required for a full dose (490 mg).
- Inspect the packaging. The on-body injectors or cartridges should not be used if they have been dropped or appear to be broken or damaged.
- Wait at least 45 minutes for the on-body injectors and prefilled cartridges in the cartons to naturally reach room temperature prior to administration. Do not return to the refrigerator. Discard after 3 days if unused.
- Before administration, visually inspect the solution. The solution should not be injected if it contains flakes or particles, or is cloudy or discolored.
Subcutaneous Administration of ULTOMIRIS On-Body Delivery System
ULTOMIRIS on-body delivery system is for subcutaneous administration into the abdomen, thigh, or upper arm region. A patient may self-administer, or the patient caregiver may administer ULTOMIRIS on-body delivery system after the healthcare provider determines it is appropriate. Injection sites should be rotated, and injections should not be given into areas where the skin is tender, bruised, red, or hard. Avoid injecting into areas with scars or stretch marks. The 2 on-body delivery systems can be administered concurrently or sequentially. Each injection is delivered over approximately 10 minutes.
- Load the first clean cartridge into the first on-body injector and secure in place before closing the cartridge door on the injector. Do not insert the cartridge more than 5 minutes before the injection to avoid drying out the solution.
- Peel away the adhesive backing of the first on-body injector and apply onto the clean, dry, chosen injection site (thigh, abdomen, or upper arm).
- Start the injection by firmly pressing and releasing the blue start button.
- Do not remove until the injection is complete (signaled by the solid green status light, 3 beeping sounds, and the white plunger filling the medicine window).
- Repeat steps 1-4 for the second on-body injector.
If an allergic reaction occurs during the subcutaneous administration of ULTOMIRIS, treatment should be stopped, the on-body injector(s) should be removed, and the patient should seek medical attention prior to further administration.
The patient should monitor for signs or symptoms of infusion-related reaction for at least 1 hour following completion of the injection.
Any unused medicinal product and waste material should be disposed of in accordance with local requirements.